Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections
- PMID: 6218778
- PMCID: PMC185717
- DOI: 10.1128/AAC.22.6.1037
Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections
Abstract
In four patients with Pseudomonas aeruginosa infections, the infecting strain developed resistance to moxalactam during therapy with this drug. In addition, P. aeruginosa isolates from two of these four patients showed increased resistance to aminoglycosides. Isolates from a third patient acquired cross-resistance to other antipseudomonal beta-lactams. In three of the cases, disk susceptibility tests failed to detect the resistance that was demonstrated in broth dilution assays. Isolate identities were confirmed by serotyping. No new plasmids were found by agarose gel electrophoresis. The mechanisms for this resistance did not involve enzymatic antibiotic degradation. These findings suggest that currently available expanded-spectrum cephalosporin derivatives should probably not be used alone for most serious infections due to P. aeruginosa. They also suggest that strains with multiple antibiotic resistance may become more prevalent in hospitals if these drugs are used extensively.
Similar articles
-
Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.Antimicrob Agents Chemother. 1980 Apr;17(4):750-6. doi: 10.1128/AAC.17.4.750. Antimicrob Agents Chemother. 1980. PMID: 6446880 Free PMC article.
-
Occurrence of antipseudomonal beta-lactams and aminoglycosides resistance in Pseudomonas aeruginosa during therapy.Microbiologica. 1987 Jan;10(1):103-10. Microbiologica. 1987. PMID: 3106759
-
[Susceptibility of recent clinical isolates of Pseudomonas aeruginosa and Serratia marcescens to cefotaxime, ceftizoxime, cefmenoxime, latamoxef and cefsulodin in comparison with other beta-lactam antibiotics and aminoglycosides].Jpn J Antibiot. 1982 Sep;35(9):2314-7. Jpn J Antibiot. 1982. PMID: 6292543 Japanese. No abstract available.
-
New drug evaluations: moxalactam (Moxam, Eli Lilly).Drug Intell Clin Pharm. 1982 Feb;16(2):104-12. doi: 10.1177/106002808201600203. Drug Intell Clin Pharm. 1982. PMID: 6210519 Review.
-
An evaluation of antipseudomonal antimicrobic agents.Antibiot Chemother (1971). 1985;36:111-33. doi: 10.1159/000410477. Antibiot Chemother (1971). 1985. PMID: 3923909 Review.
Cited by
-
In vitro activity of BRL 36650, a new semisynthetic penicillin.Antimicrob Agents Chemother. 1986 Jun;29(6):972-6. doi: 10.1128/AAC.29.6.972. Antimicrob Agents Chemother. 1986. PMID: 3755315 Free PMC article.
-
An international study on the occurrence of multiresistant bacteria and aminoglycoside consumption patterns.Infection. 1988 Sep-Oct;16(5):313-22. doi: 10.1007/BF01645084. Infection. 1988. PMID: 3215695
-
Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins.Eur J Clin Microbiol. 1987 Aug;6(4):456-9. doi: 10.1007/BF02013110. Eur J Clin Microbiol. 1987. PMID: 3499316
-
In vitro comparison of Pseudomonas aeruginosa isolates with various susceptibilities to aminoglycosides and ten beta-lactam antibiotics.Antimicrob Agents Chemother. 1984 Apr;25(4):488-90. doi: 10.1128/AAC.25.4.488. Antimicrob Agents Chemother. 1984. PMID: 6428308 Free PMC article.
-
Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa.Antimicrob Agents Chemother. 1985 Jul;28(1):41-5. doi: 10.1128/AAC.28.1.41. Antimicrob Agents Chemother. 1985. PMID: 3929679 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical